Discover the full directors' dealings record of R1 RCM INC., a listed equity based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, R1 RCM INC. has logged 75 reports. The latest transaction was filed on 23 May 2022 — Levée d'options. Among the most active insiders: TERSIGNI ANTHONY R. All data is openly available.
25 of 75 declarations
R1 RCM Inc. (ticker: RCM) is a US-listed healthcare services and technology company traded on the NASDAQ in the United States. For international investors, R1 is best understood as a specialist in healthcare revenue cycle management (RCM): it helps hospitals, health systems, and physician groups improve how they register patients, verify coverage, code services, submit claims, collect payments, and manage denials. The company combines operational outsourcing, software, workflow automation, analytics, and increasingly AI-enabled tools to support a provider’s financial performance. R1 was founded in the early 2000s and has built a long operating history of more than two decades in healthcare revenue management. Its corporate footprint is associated with Chicago, with operational presence also linked to Murray, Utah, reflecting a distributed US-based delivery model. Over time, the company has evolved from a traditional services provider into a more technology-led platform, emphasizing enterprise software, automation, and digital transformation across the revenue cycle. The company’s main service lines center on end-to-end or modular RCM solutions. These typically include patient access and scheduling support, eligibility verification, charge capture, coding support, claims management, denial resolution, collections, payment integrity, and financial performance improvement. More recently, R1 has been positioning its AI and automation strategy around Phare, which it describes as healthcare’s first revenue operating system, and R37, its AI innovation lab designed to bring more agentic automation into healthcare financial operations. From a competitive standpoint, R1 operates in a large but highly fragmented market where hospitals face intense margin pressure, labor constraints, and growing administrative complexity. R1’s value proposition is its scale, process expertise, and technology stack, which it presents as a way to reduce cost to collect, improve yield, and accelerate cash flow. The company says it works with 95 of the top 100 US health systems, a strong indicator of its position among large enterprise healthcare providers. Geographically, R1 is primarily concentrated in the United States, where its client base is overwhelmingly located, although its workflows and systems serve multi-facility healthcare organizations with national reach. Recent strategic highlights include the launch and expansion of Phare in 2025 and 2026, a strategic AI partnership with Sierra, and an investment from Khosla Ventures in May 2025 that underscored market interest in R1’s AI-led transformation narrative. For investors, the key theme is that R1 is no longer just a revenue cycle outsourcer; it is increasingly presenting itself as a healthcare financial technology platform focused on automation, resilience, and operating leverage.